AZN

Q: What is the price of AstraZeneca (AZN) today?

The current price of AstraZeneca (AZN) is $ 200.47, representing a 50.95% gain over the past year. The stock began the year trading around $ 91.57 and is currently priced at $ 200.47. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

Q: When does AstraZeneca (AZN) pay dividends?

In the last year, AstraZeneca (AZN) distributed dividends in the month of March, totaling $ 2.17. The Dividend Yield for the last 12 months is 1.55%.

Q: Is AstraZeneca (AZN) a good investment?

AstraZeneca (AZN) is currently trading at $ 200.47 with a P/E ratio of 31.27%. This represents a 3,793% premium compared to its historical average P/E. Over the past year, the stock has gained 50.95 and paid $ 2.17 in dividends, resulting in a dividend yield of 1.55%. The total shareholder return over the same period was 50.95%.Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

AstraZeneca PLC

Price

$ 200.47

return (12m)

50.95%

p/e

31.27

p/bv

6.56

DIVIDEND YIELD

1.55%

AZN price

AZN

If you had invested

years ago

7 days

30 days

6 months

YTD

1 year

5 years

10 years

ago, you would now have *

ago, you would now have:

*The figure considers the reinvestment of dividends.

Return on Investment AZN

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

5.93%

3 months

12.64%

1 year

50.95%

2 years

51.95%

5 years

115.83%

10 years

343.32%

Fundamentals AZN

review the fundamentals of AstraZeneca shares

P/E

31.27

Sector: -3.96 Industry: -3.96

P/S (PSR)

5.44

Sector: -3.88 Industry: -3.88

P/BV

6.56

Sector: 1.87 Industry: 1.87

DIVIDEND YIELD (DY)

1.55%

Sector: - Industry: -

ROA

8.96%

Sector: -61.39% Industry: -61.39%

ROE

20.99%

Sector: -60.71% Industry: -60.71%

ROIC

10.51%

Sector: -1,194.93% Industry: -1,194.93%

NET MARGIN

17.41%

Sector: -39.39% Industry: -39.39%

GROSS MARGIN

81.90%

Sector: 38.09% Industry: 38.09%

OPERATING MARGIN

23.40%

Sector: -39.58% Industry: -39.58%

EV/EBITDA

16.32

Sector: -3.80 Industry: -3.80

EV/EBIT

22.67

Sector: -4.02 Industry: -4.02

PRICE-TO-ASSETS

2.80

Sector: 1.38 Industry: 1.38

BVPS

31.41

Sector: 1.89 Industry: 1.89

EPS

6.59

Sector: -2.05 Industry: -2.05

EQUITY-TO-ASSETS RATIO

0.43

Sector: 0.42 Industry: 0.42

LIABILITIES / ASSETS

0.57

Sector: 0.39 Industry: 0.39

CAGR REVENUE 5 YEARS

9.44%

Sector: - Industry: -

CAGR PROFIT 5 YEARS

146.65%

Sector: - Industry: -

FAIR VALUE OF AstraZeneca ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$ 200.47

Fair Value

$ 0.00

Upside/Downside Return potential.

-65.96%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals AZN

DRAG THE FRAME TO SEE MORE DATA

Stock Comparison Tool

DRAG THE FRAME TO SEE MORE DATA

	p/e	p/bv	ROE	dy	market cap	net margin
JNJ	21.88	7.40	33.81%	2.14%	$ 586.59 B	28.46%
PFE	20.06	1.67	8.35%	6.28%	$ 155.85 B	12.42%
ABBV	89.02	0.00	0.00%	3.12%	$ 376.19 B	6.91%
NVO	10.61	5.46	51.50%	4.98%	$ 166.18 B	33.05%
MRK	16.72	0.00	0.00%	2.70%	$ 305.21 B	28.08%
GILD	20.77	7.81	37.62%	2.24%	$ 176.72 B	28.90%
BMY	16.98	-3.52	-20.72%	4.23%	$ 119.74 B	14.64%
ZTS	19.59	15.72	80.25%	1.70%	$ 52.37 B	28.23%
REGN	17.51	2.52	14.41%	0.47%	$ 78.86 B	31.41%
HALO	24.94	161.91	649.21%	0.00%	$ 7.90 B	22.69%
AMGN	24.97	22.24	89.06%	2.70%	$ 192.51 B	20.98%
MCK	24.84	-1,089.08	-4,383.84%	0.36%	$ 107.82 B	1.09%
VRTX	28.42	6.02	21.18%	0.00%	$ 112.36 B	32.94%
CAH	30.78	-18.95	-61.56%	0.94%	$ 51.16 B	0.68%
HRMY	10.31	1.88	18.24%	0.00%	$ 1.64 B	18.27%
ADMA	16.29	5.01	30.78%	0.00%	$ 2.39 B	28.80%
BIIB	20.21	1.43	7.08%	0.00%	$ 26.12 B	13.07%

Stock vs Indice Comparison Tool

If you had invested (change) 2 years years ago, ago, you would now have

R$ 1.000,00 in PETR4 You would now have R$ 2.294,60

R$ 1.000,00 in LEVE3 You would now have R$ 5.240,60

*The value considers the reinvestment of dividends.

AZN Historical Dividends

current DY: 1.55%

5-year average DY: 2.22%

DRAG THE FRAME TO SEE MORE DATA

type	Ex - Dividend Date	payment date	value
Dividends	02/20/2026	03/23/2026	2,17190000
Dividends	08/08/2025	09/08/2025	1,03000000
Dividends	02/21/2025	03/24/2025	2,10000000
Dividends	08/09/2024	09/09/2024	1,00000000
Dividends	02/23/2024	03/25/2024	1,97000000
Dividends	08/11/2023	09/11/2023	0,93000000
Dividends	02/24/2023	03/27/2023	1,97000000
Dividends	08/12/2022	09/12/2022	0,93000000
Dividends	02/25/2022	03/28/2022	1,97000000
Dividends	08/13/2021	09/13/2021	0,90000000
Dividends	02/26/2021	03/29/2021	1,90000000
Dividends	08/14/2020	09/14/2020	0,90000000
Dividends	02/28/2020	03/30/2020	1,90000000
Dividends	08/09/2019	09/09/2019	0,90000000
Dividends	03/01/2019	03/27/2019	1,90000000
Dividends	08/10/2018	09/10/2018	0,90000000
Dividends	02/16/2018	03/19/2018	1,90000000
Dividends	08/11/2017	09/11/2017	0,90000000
Dividends	02/17/2017	03/20/2017	1,90000000
Dividends	08/12/2016	09/12/2016	0,90000000
Dividends	02/19/2016	03/21/2016	1,90000000
Dividends	08/14/2015	09/14/2015	0,90000000
Dividends	02/20/2015	03/23/2015	1,90000000
Dividends	08/15/2014	09/15/2014	0,90000000
Dividends	02/21/2014	03/24/2014	1,90000000
Dividends	08/16/2013	09/16/2013	0,90000000
Dividends	02/15/2013	03/18/2013	1,90000000
Dividends	08/10/2012	09/10/2012	0,90000000
Dividends	02/17/2012	03/19/2012	1,95000000
Dividends	08/08/2011	09/12/2011	0,85000000
Dividends	02/04/2011	03/14/2011	1,85000000
Dividends	08/06/2010	09/13/2010	0,70000000
Dividends	02/05/2010	03/15/2010	1,71000000
Dividends	08/07/2009	09/14/2009	0,59000000
Dividends	02/06/2009	03/16/2009	1,50000000
Dividends	08/08/2008	09/15/2008	0,55000000
Dividends	02/11/2008	03/17/2008	1,35000000
Dividends	08/10/2007	09/17/2007	0,52000000
Dividends	02/09/2007	03/19/2007	1,23000000
Dividends	08/11/2006	09/18/2006	0,49000000
Dividends	02/10/2006	03/20/2006	0,92000000
Dividends	08/12/2005	09/19/2005	0,38000000
Dividends	02/11/2005	03/21/2005	0,64500000
Dividends	08/13/2004	09/20/2004	0,29500000
Dividends	02/20/2004	04/06/2004	0,54000000
Dividends	08/22/2003	10/06/2003	0,25500000
Dividends	02/21/2003	04/07/2003	0,52200000
Dividends	08/23/2002	10/07/2002	0,25600000
Dividends	02/22/2002	04/08/2002	0,52200000
Dividends	08/24/2001	10/05/2001	0,25600000
Dividends	02/23/2001	04/09/2001	0,52200000
Dividends	09/08/2000	10/23/2000	0,25600000
Dividends	03/10/2000	04/17/2000	0,52200000
Dividends	09/10/1999	10/25/1999	0,25600000
Dividends	04/09/1999	04/28/1999	0,35000000

ABOUT AstraZeneca

AstraZeneca PLC

Average Investor10 user rating

4.0 (114 people)

United States

34 years

Founded: 1992

1993

Time since IPO - 33 years

74.800

Employees

AstraZeneca is a U.K.-based global biopharmaceutical company operating in the Healthcare sector. Established in the late 1990s and headquartered in Cambridge, United Kingdom, the company focuses on the research, development, and commercialization of prescription medicines.

AstraZeneca concentrates its portfolio on several key therapeutic areas:

Oncology: Treatments for multiple types of cancer.
Cardiovascular, Renal and Metabolism: Therapies addressing heart disease and related conditions.
Respiratory and Immunology: Medicines for asthma, COPD, and inflammatory diseases.
Infectious Diseases: Antiviral and vaccine-related solutions.
Neuroscience: Research and treatments for disorders affecting the central nervous system.

The company operates in more than 100 countries and maintains a broad global manufacturing and commercial footprint. It also owns Alexion Pharmaceuticals, a subsidiary focused on rare diseases and specialty therapies.

AstraZeneca supports its innovation pipeline through a network of research and development centers across Europe, North America, and Asia. Its shares trade on the London Stock Exchange (LSE) under AZN and in the United States as American Depositary Receipts (ADRs) under the ticker AZN on the Nasdaq.

History and Development

AstraZeneca was formed in the late 1990s through the merger of Sweden-based Astra AB and the U.K.-based Zeneca Group, creating a multinational pharmaceutical company with a diversified research portfolio.

Following the merger, the company expanded globally, strengthening its presence in key markets and investing in advanced research infrastructure.

Throughout the 2000s and 2010s, AstraZeneca pursued strategic acquisitions and partnerships to reinforce its pipeline in oncology, biologics, and rare diseases. These transactions broadened its therapeutic focus and increased its exposure to high-growth specialty areas.

In recent years, the company has emphasized innovation in oncology and immunology, as well as biologic medicines and rare disease treatments through its subsidiary operations.

Beginning in the early 2020s, AstraZeneca gained additional global visibility through vaccine development and large-scale international distribution efforts. The company continues to invest heavily in research, aiming to expand its portfolio of advanced therapies and maintain its position among the world’s leading pharmaceutical manufacturers.

Additional Information

AstraZeneca PLC (United States) is listed on the Nasdaq and has a market capitalization of $319.77 Billions, with shareholders equity totaling $48.72 Billions.

The company employs approximately 74.800 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, AstraZeneca PLC reported $58.74 Billions in revenue, generating net income of $10.23 Billions.

Key financial metrics include a P/E ratio of 31.27, a price-to-book (P/B) ratio of 6.56, and a trailing twelve-month dividend yield of 1.55%.

The company trades under the ticker AZN.

Market cap

$ 319.77 Billions

Net worth

$ 48.72 Billions

$ 48,719,000,000.00

Assets

$ 114.07 Billions

$ 114,074,000,000.00

Total Shares Outstanding

1.55 Billion

1,551,000,000

Average Daily Trading Volume

$ 2.21 Millions

$ 2,207,647.06

Sector

Health Care

Industry

Biotechnology

AZN

AZN revenue and profits

Financial Results AZN

DRAG THE FRAME TO SEE MORE DATA

AZN cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more stocks

BFRA - Biofrontera

$ - -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$ 867.34 24,92% (12M)

P/E

24.84

0.36%

ROE

-4,383.84%

P/BV

-1,089.08

CAH - Cardinal Health

$ 213.10 59,98% (12M)

P/E

30.78

0.94%

ROE

-61.56%

P/BV

-18.95

JNJ - Johnson & Johnson

$ 234.54 53,09% (12M)

P/E

21.88

2.14%

ROE

33.81%

P/BV

7.40

PFE - Pfizer

$ 27.22 31,87% (12M)

P/E

20.06

6.28%

ROE

8.35%

P/BV

1.67

ABBV - AbbVie

$ 208.99 25,80% (12M)

P/E

89.02

3.12%

ROE

0.00%

P/BV

0.00

MRK - Merck & Co.

$ 115.46 53,40% (12M)

P/E

16.72

2.70%

ROE

0.00%

P/BV

0.00

BMY - Bristol-Myers Squibb

$ 58.96 27,11% (12M)

P/E

16.98

4.23%

ROE

-20.72%

P/BV

-3.52

BFRA - Biofrontera

$ - -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$ 867.34 24,92% (12 M)

P/L

24.84

0.36%

ROE

-4,383.84%

P/VP

-1,089.08

CAH - Cardinal Health

$ 213.10 59,98% (12 M)

P/L

30.78

0.94%

ROE

-61.56%

P/VP

-18.95

JNJ - Johnson & Johnson

$ 234.54 53,09% (12 M)

P/L

21.88

2.14%

ROE

33.81%

P/VP

7.40

PFE - Pfizer

$ 27.22 31,87% (12 M)

P/L

20.06

6.28%

ROE

8.35%

P/VP

1.67

ABBV - AbbVie

$ 208.99 25,80% (12 M)

P/L

89.02

3.12%

ROE

0.00%

P/VP

0.00

MRK - Merck & Co.

$ 115.46 53,40% (12 M)

P/L

16.72

2.70%

ROE

0.00%

P/VP

0.00

BMY - Bristol-Myers Squibb

$ 58.96 27,11% (12 M)

P/L

16.98

4.23%

ROE

-20.72%

P/VP

-3.52

Frequently Asked Questions

What is the price of AstraZeneca (AZN) today?

The current price of AstraZeneca (AZN) is $ 200.47, representing a 50.95% gain over the past year. The stock began the year trading around $ 91.57 and is currently priced at $ 200.47. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

When does AstraZeneca (AZN) pay dividends?

In the last year, AstraZeneca (AZN) distributed dividends in the month of March, totaling $ 2.17. The Dividend Yield for the last 12 months is 1.55%.

Is AstraZeneca (AZN) a good investment?

AstraZeneca (AZN) is currently trading at $ 200.47 with a P/E ratio of 31.27%. This represents a 3,793% premium compared to its historical average P/E. Over the past year, the stock has gained 50.95 and paid $ 2.17 in dividends, resulting in a dividend yield of 1.55%. The total shareholder return over the same period was 50.95%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy AstraZeneca (AZN) stock?

You can buy AstraZeneca (AZN) shares through any brokerage account that provides access to U.S. stock exchanges. After opening and funding your account, simply search for the ticker symbol AZN and place a buy order. Before investing, consider factors such as your financial goals, risk tolerance, and overall portfolio allocation.

How much would 100 shares of AstraZeneca (AZN) yield today?

Over the past month, AstraZeneca (AZN) has returned 5.93% — 50.95% over the past year, and 115.83% over the past five years, including price appreciation and dividends.

In the last 12 months, the company paid a total of 2.69 per share in dividends, resulting in a dividend yield of 1.55%.

If you were to purchase 100 shares of AstraZeneca (AZN) today at the current price of $ 200.47 your total investment would be $ 20,047.00.

Based on historical performance, the investment would have grown to approximately:

$ 30,260.95 after 1 year
$ 43,267.44 after 5 years
$ 88,872.36 after 10 years

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

AZN

AstraZeneca PLC

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment AZN

review the fundamentals of AstraZeneca shares

P/E

P/S (PSR)

P/BV

DIVIDEND YIELD (DY)

ROA

ROE

ROIC

NET MARGIN

GROSS MARGIN

OPERATING MARGIN

EV/EBITDA

EV/EBIT

PRICE-TO-ASSETS

BVPS

EPS

EQUITY-TO-ASSETS RATIO

LIABILITIES / ASSETS

CAGR REVENUE 5 YEARS

CAGR PROFIT 5 YEARS

Graham's Fair Value

If you had invested (change) 2 years years ago, ago, you would now have

current DY: 1.55%

5-year average DY: 2.22%

type

Ex - Dividend Date

payment date

value

ABOUT AstraZeneca

AstraZeneca PLC

United States

34 years

1993

74.800

History and Development

Additional Information

PROFIT X PRICE AZN

Financial Results AZN

AZN cash flow

Asset, Revenue and Profit Growth - AZN

AZN balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

PFE - Pfizer

ABBV - AbbVie

MRK - Merck & Co.

BMY - Bristol-Myers Squibb

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

PFE - Pfizer

ABBV - AbbVie

MRK - Merck & Co.

BMY - Bristol-Myers Squibb

Frequently Asked Questions